Generated by AI
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions. Rocket Pharmaceuticals currently develops and advances investigational and commercial genetic medicines, including therapies for disorders such as Danon disease, BAG3-related dilated cardiomyopathy, Fanconi anemia, and severe leukocyte adhesion deficiency-I. The company is also involved in manufacturing, clinical development, and the commercialization of its gene therapy products. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals plays a specialized role in the rare-disease market by targeting conditions with significant unmet medical need through precision genetic medicine.
Website9 Cedarbrook Drive
Cranbury, NJ, 08512
United States
The latest articles about RCKT.
Analyst rates Rocket Pharmaceuticals a Hold: KRESLADI onboarding and cardiovascular validation must advance before a bullish view; shares trade at 0.71x...
Rocket Pharmaceuticals charts pivotal Phase 2 path for Danon disease gene therapy RP-A501. Read more here.
Summary of Oct 7's posts. Generated by AI.
Summary of Jun 29's posts. Generated by AI.
Summary of Aug 10's posts. Generated by AI.
Investors talking about RCKT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.